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Hepáticas y Digestivas (CIBERehd), SpainPortal hypertension is the main cause of complications in or recurrent variceal bleeding, and on the short-term intravenous
patients with chronic liver disease. Over the past 25 years, pro-
gress in the understanding of the pathophysiology of portal
hypertension was followed by the introduction of an effective
pharmacological therapy, consisting mainly of treatments aimed
at correcting the increased splanchnic blood ﬂow. It is only
recently that this paradigm has been changed. Progress in our
knowledge of the mechanisms of increased resistance to portal
blood ﬂow, of the formation of portal-systemic collaterals, and
of mechanisms other than vasodilatation maintaining the
increased splanchnic blood ﬂow have opened entirely new per-
spectives for developing more effective treatment strategies. This
is the aim of the current review, which focuses on: (a) the mod-
ulation of hepatic vascular resistance by correcting the increased
hepatic vascular tone due to hepatic endothelial dysfunction, and
(b) correcting the abnormal angiogenesis associated with portal
hypertension, which contributes to liver inﬂammation and ﬁbro-
genesis, to the hyperkinetic splanchnic circulation, and to the for-
mation of portal-systemic collaterals and varices.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Portal hypertension is a very frequent and dreadful complication
of chronic liver disease. Its consequences, mainly bleeding from
gastro-esophageal varices and portal hypertensive gastropathy,
ascites, spontaneous bacterial peritonitis, hepatorenal syndrome,
hepatopulmonary syndrome, portopulmonary hypertension,
hyperkinetic syndrome, and hepatic encephalopathy, carry a poor
prognosis and represent the ﬁrst cause of death and need for liver
transplantation in patients with cirrhosis [1].
Over the past 25 years, progress in the understanding of the
pathophysiology of portal hypertension was followed by the
introduction of effective pharmacological therapy, consisting
mainly of the continued oral administration of non-selective
beta-blockers (propranolol, nadolol) for the prevention of ﬁrstJournal of Hepatology 20
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E-mail address: jbosch@clinic.ub.es (J. Bosch).infusion of terlipressin, somatostatin, or somatostatin analogs for
acute variceal bleeding [1,2]. These treatments were aimed at
correcting the increased splanchnic blood ﬂow, that was shown
at this moment to contribute to maintain and aggravate portal
hypertension [3]. Some of these agents (NSBB, terlipressin) act
by decreasing the cardiac index and causing splanchnic arterial
vasoconstriction [2], while the effects of somatostatin are more
linked to suppressing glucagon secretion [4] and facilitating
adrenergic vasoconstricition [5].
It is only recently that this paradigm has been changed. Pro-
gress in our knowledge of the mechanisms of increased resis-
tance to portal blood ﬂow, of the formation of portal-systemic
collaterals, and of mechanisms other than vasodilatation main-
taining the increased splanchnic blood ﬂow have opened entirely
new perspectives for developing more effective treatment strate-
gies (Fig. 1). This is the aim of the current review, which focuses
on the modulation of hepatic vascular resistance by correcting
the increased hepatic vascular tone due to hepatic endothelial
dysfunction [2], and on correcting the abnormal angiogenesis
associated with portal hypertension, which contributes to liver
inﬂammation and ﬁbrogenesis, to hyperkinetic splanchnic circu-
lation, and to the formation of portal-systemic collaterals and
varices [6].Modulation of intra-hepatic endothelial dysfunction
Increased intra-hepatic resistance to portal blood ﬂow is the pri-
mary factor leading to portal hypertension in cirrhosis. Much of
the increased intra-hepatic resistance is the mechanical conse-
quence of the architectural disturbances caused by the cirrhotic
process. However, in recent years it has become clear that on
top of these alterations there is an active contraction of several
elements in the liver that further contribute to increase resis-
tance. It has been claimed that this dynamic and reversible com-
ponent of intra-hepatic resistance may represent 30–40% of the
total increased intra-hepatic vascular resistance in cirrhosis. Con-
tractile elements inﬂuencing the hepatic vascular bed can be
located at sinusoidal as well as extrasinusoidal levels and include
vascular smooth muscle cells of the intra-hepatic vasculature (i.e.
small portal venules in portal areas) [7], activated hepatic stellate
cells (HSCs) (pericyte cells located in the perisinusoidal space of
Disse with extensions that wrap around the sinusoids and reduce
its caliber after contraction) [8,9], and hepatic myoﬁbroblasts10 vol. 53 j 558–567
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Fig. 1. Rationale basis for the treatment of portal hypertension.While current
treatments are based on the use of drugs that decrease blood ﬂow by attenuating
the splanchnic vasodilatation (old paradigm), new treatments aim at correcting
the increased hepatic vascular resistance and the formation of portal-systemic
collaterals (new paradigm).
JOURNAL OF HEPATOLOGYthat may compress the regenerating nodules or venous shunts
within the ﬁbrous septa. It is now clear that vasoactive mediators,
either vasoconstrictors or vasodilators, may modulate intra-
hepatic vascular resistance either in health or during liver dis-
ease, whatever the location where they act.
In normal conditions, the endothelium is able to generate
vasodilatory factors in response to increases in blood volume,
blood pressure, or vasoconstrictor agents, in an attempt to pre-
vent or attenuate the concomitant increase in intravascular
pressure. In several pathological conditions there is an impair-
ment in this endothelium-dependent vasodilatation, a condition
that has been named as ‘‘endothelial dysfunction” [10,11]. The
hepatic vascular bed of cirrhotic livers also exhibits endothelial
dysfunction [12]. Indeed, contrary to what happens in normal
livers, the cirrhotic liver cannot accommodate the increased
portal blood ﬂow caused by the post-prandial hyperemia, which
determines an abrupt post-prandial increase in portal pressure
[13]. In addition, in experimental models of cirrhosis, endothe-
lial dysfunction has been further characterized by showing that
the cirrhotic liver exhibits an impaired response to the endothe-
lium-dependent vasodilator acetylcholine (ACH) [12,14]. Endo-
thelial dysfunction in cirrhosis has been attributed to reduce
nitric oxide (NO) bioavailability and to increased vasoconstrictor
COX-1 derived prostanoids and it is also thought to be impli-
cated in the pathogenesis of the dynamic component of the
increased intra-hepatic resistance of the cirrhotic liver. Such
imbalance between endogenous vasoconstrictor and vasodilator
factors observed in the cirrhotic liver is quite similar to that
found in the systemic circulation in patients with arterial hyper-
tension. This is why the extensive advances in cardiovascular
research have contributed enormously to an improved knowl-
edge of the pathophysiology of portal hypertension. The main
factors involved are described below.Journal of Hepatology 201COX derived prostanoids
Cyclooxygenase (COX) is the key enzyme in the biosynthetic
pathway leading to the production of prostaglandins (PGs) and
thromboxane (TX) from arachidonic acid (AA) [15]. COX-1 is con-
stitutively expressed but it can also be stimulated by different
factors [16,17]. COX-2 is the inducible isoform of COX that is usu-
ally expressed after stimulation with proinﬂammatory agents
[18]. However, it has also been shown to be constitutively
expressed in some tissues, including the liver [14] [19] and the
mesenteric vascular bed [20].
Much evidence supports the involvement of COX-1 derived
prostanoids promoting the increase in resistance to portal blood
ﬂow of cirrhotic livers. Indeed, the hyper-response of the hepatic
vasculature of cirrhotic livers to the vasoconstrictor alfa1-agonist
methoxamine is associated with an overproduction of thrombox-
ane A2 (TXA2) by COX-1 and it is completely corrected by pre-
treating the livers with non-selective COX blockers, COX-1 selec-
tive blockers, or TXA2 receptor antagonists [19]. Similarly, it has
been demonstrated that the endothelial dysfunction of cirrhotic
livers, is also associated with an increased production of TXA2
and completely prevented by selective COX-1 blockers and
TXA2 antagonists. These results suggest that an increased pro-
duction of a COX-1 derived vasoconstrictor prostanoid, probably
TXA2, is at least in part, responsible for the presence of endothe-
lial dysfunction [14].
Sinusoidal endothelial cells are the major contributor to the
increased production of vasoconstrictors prostanoids (TXA2,
and probably also prostaglandin H2) [21]. Moreover, the
increased phospholipase A2 activity observed in cirrhotic rat liv-
ers, by increasing AA bioavailability, is an additional mechanism
contributing to the increased generation of vasoconstrictor pros-
tanoids [21]. On the other hand, it has been suggested that Kupf-
fer cell activation is also involved in the increased portal pressure
of ﬁbrotic livers via TXA2 generation [22]. All these ﬁndings sug-
gest that in cirrhotic livers there is an over-activation of the COX-
1 pathway with an increased production of their vasoconstrictor-
derived compounds, and that correcting these abnormalities will
have beneﬁcial effects on hepatic circulation.Reduced nitric oxide (NO) bioavailability within the cirrhotic liver
NO is the natural ligand for soluble guanylate cyclase and is
responsible for an increase in cyclic guanosine monophosphate
(cGMP), the ﬁnal agent responsible for the relaxation of the vas-
cular wall through the extrusion of cytosolic Ca2+. Endothelial NO
synthase (eNOS) is responsible for most of the vascular NO pro-
duced in a reaction where L-arginine is oxidized to L-citrulline
and NO [23]. In the cirrhotic liver, there is a reduced NO bioavail-
ability that plays a major role in increasing intra-hepatic vascular
resistance and thereby worsening portal hypertension. Decreased
NO production occurs despite a normal expression of eNOS
mRNA and normal levels of eNOS protein [12,24], and has been
attributed, at least in part, to reduced eNOS activity caused by
several posttranslational alterations in the regulation of the
enzyme such as increased caveolin expression, or a defect of
the essential cofactor of eNOS, tetrahydrobiopterin (BH4),
decreased eNOS phosphorylation, and increased levels of asym-
metric dimethylarginine among others [25,26] (Table 1). In accor-
dance with these pathophysiological abnormalities several efforts0 vol. 53 j 558–567 559
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Reviewto improve NO bioavailability within the liver have been
attempted.
The ﬁrst attempt was the exogenous administration of NO
donors. In that regard, the administration of nitrates such as iso-
sorbide-5-mononitrate has been shown to decrease portal pres-
sure. The major concern with the use of these drugs in patients
with advanced cirrhosis is that, by reducing arterial blood pres-
sure, they may promote the activation of endogenous vasoactive
systems that ﬁnally may lead to water and sodium retention [15].
NCX-1000, a NO-releasing derivative of ursodeoxycolic acid
(UDCA), was designed to selectively target intra-hepatic circula-
tion by delivering NO only to the intra-hepatic site, with the
aim to effectively reduce the baseline hepatic venous pressure
gradient (HVPG) and to counteract the post-prandial increase in
portal pressure, without adverse effects on systemic and splanch-
nic circulation. Results from experimental models were promis-
ing [27]. However, in a recent study in cirrhotic patients with
portal hypertension, NCX-1000 treatment did not reduce baseline
HVPG while it decreased hepatic blood ﬂow and systolic blood
pressure. In addition, NCX-1000 did not modify the post-prandial
increase in HVPG [28]. Thus, this agent failed to prove efﬁcacious
for the treatment of portal hypertension. This was mainly due to
poor bioavailability, and to the lack of a speciﬁc intra-hepatic
vasodilatory effect [28]. The search for an effective way of specif-
ically supplementing NO to liver circulation, thus reducing portal
pressure without affecting systemic arterial pressure, is still
warranted.
Other strategies to correct the intra-hepatic NO deﬁciency
have been based on either overexpressing NOS by transfecting
the liver with adenovirus encoding eNOS [29,30], nNOS [31], or
constitutively active Akt [32], by enhancing eNOS activity by sim-
vastatin (a HMG-CoA reductase inhibitor) [33,34], by decreasing
NO scavenging by means of antioxidants [35,36], by administer-
ing the eNOS cofactor tetrahydrobiopterin [37] or scavenging NO
by reactive oxygen species (ROS) due to oxidative stress [38]
(Table 1). The possible role of statins, tetrahydrobiopterin
(BH4), and oxidative stress are the strategies more extensively
studied.
The role of statins in the treatment of portal hypertension
The ideal drug for portal hypertension was recently pictured as
one that should reduce portal pressure by decreasing intra-hepa-560 Journal of Hepatology 201tic vascular resistance, while maintaining or enhancing hepatic
blood ﬂow [39]. Other desirable actions would be an antiﬁbrotic
effect and a capacity to improve liver function. A drug that would
be able to increase nitric oxide bioavailability in the liver would
fulﬁl many of these requirements [29,31,32,39,40].
HMG-CoA reductase inhibitors, commonly called statins, are
widely used lipid lowering drugs that have additional beneﬁcial
effects over the peripheral vasculature by enhancing NO produc-
tion in endothelial cells [41–46]. This occurs by enhancing both
the expression of the endothelial nitric oxide synthase (eNOS)
and its activity at the posttranslational level, by acting on multi-
ple mechanisms modulating eNOS activity [43,47,48] (Fig. 2).
This led us to hypothesize that statins could be useful for enhanc-
ing NO production in the liver circulation [34] and, thus, they
could have potential for the treatment of portal hypertension.
Indeed, consistent experimental [33,49] and human studies [34]
suggested that statins were able to decrease intra-hepatic vascu-
lar resistance and improve ﬂow-mediated vasodilation of liver
vasculature in the cirrhotic liver by selectively enhancing endo-
thelial NO production in the liver, without further enhancing
arterial vasodilation. In addition, statins have been shown to inhi-
bit hepatic RhoA/Rho kinase signalling, which would decrease
hepatic stellate cell (HSC) contraction by a NO independent
(and, thus, endothelium independent) mechanism [49]. Alto-
gether, this indicates that these drugs could behave as true
liver-selective vasodilators [33,34,49]. Subsequently, a multicen-
ter double-blind randomized controlled trial, including 59 cir-
rhotic patients with severe portal hypertension, demonstrated
that one-month simvastatin administration signiﬁcantly
decreases HVPG without inducing arterial hypotension [50]. This
occurred without modiﬁcations on liver blood ﬂow, suggesting
that simvastatin did reduce hepatic vascular resistance. The mag-
nitude of the HVPG reduction caused by simvastatin was moder-
ate (8%), but was present regardless of whether patients were
on treatment with non-selective beta-adrenergic blockers. More-
over, the effect of simvastatin was slightly greater in those taking
beta-blockers (11%), suggesting that both drugs, which act by
different mechanisms of action, have additive effects reducing
portal pressure (Fig. 3). This might be related to the fact that sim-
vastatin, by increasing NO availability in the sinusoidal circula-
tion, counteracts the effects of beta-blockers increasing liver
resistance due to unopposed alpha-adrenergic driven vasocon-
striction [51]. Another positive effect of simvastatin was a
marked improvement in hepatic clearance of indocyanine green,
which suggests that the reduction in hepatic vascular tone caused
by simvastatin improves the effective perfusion of the hepato-
cytes, with an ensuing beneﬁcial effect on liver function [50]. It
is important to note that this effect, of potential clinical rele-
vance, is observed neither with beta-blockers alone, nor associ-
ated with organic nitrates, nor with any other drug used to
treat portal hypertension. Adverse events were not different
between placebo and simvastatin, a ﬁnding that is in keeping
with the increasing number of studies reporting the safety of
statins in patients with chronic liver diseases [52–60], but the
long-term safety of statins in cirrhosis needs to be speciﬁcally
assessed.
Additional data suggest that statins might have other beneﬁ-
cial effects on cirrhosis, beyond the observed reduction in portal
pressure. A recent study showed that the continuous administra-
tion of atorvastatin prevented liver inﬂammation and hepatic
stellate cell activation induced by Angiotensin-II infusion [61].0 vol. 53 j 558–567
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Fig. 2. Mechanisms mediating the decrease in hepatic resistance by statins. Statins increase eNOS expression and activity. The most immediate effect of statins on
endothelial NO production is an increase in eNOS phosphorylation at Ser 1177/1179, with subsequent increased activity [43]. This is mediated by the activation of the
phosphatidyl inositol 3-kinase (PI3K)/Akt pathway [43] that leads to an increase in Akt phosphorylation at Ser473 with ensuing eNOS phosphorylation [47]. Statins reduce
the expression of the eNOS inhibitory protein caveolin-1 [86] and increase the interaction of eNOS with its stimulatory protein Hsp90 [86]. These effects occur slower than
the PI3K/Akt pathway activation. Statins also increase the expression of GTP cyclohydrolase I (GTPCH) [87], the rate-limiting enzyme for de novo synthesis of
tetrahydrobiopterin (BH4), a cofactor that increases eNOS activity by preventing eNOS uncoupling and, thus, superoxide generation. Statins also upregulate eNOS expression
by increasing eNOS mRNA stability [48]. Lastly, statins inhibit hepatic RhoA/Rho kinase signalling, which increases eNOS expression and decreases hepatic stellate cell
(HSC) contractility [49].
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Fig. 3. Double-blind randomized controlled trial of simvastatin vs. placebo
for portal hypertension in patients with cirrhosis. (A) HVPG decreased
signiﬁcantly in patients receiving simvastatin, but not in those receiving placebo.
(B) In the group of patients treated with simvastatin, the decrease in portal
pressure was observed both in patients under no treatment and in patients under
continuous propranolol administration, suggesting an additive effect with non-
selective beta-blockers. (modiﬁed from Abraldes et al., Gastroenterology 2009).
JOURNAL OF HEPATOLOGYFurthermore, a recent large randomized controlled trial showed
that rosuvastatin signiﬁcantly decreased the occurrence of
venous thromboembolism [62], which could be relevant in
patients with cirrhosis, who are at increased risk of portal vein
thrombosis [63,64].
The next step to take is to evaluate the potential of statins in
patients with cirrhosis in randomized controlled trials with clin-
ical end-points. The ﬁrst scenario in which statins have clear
potential is as an adjunct to beta-blockers and banding in second-
ary prophylaxis of variceal bleeding. In a recent trial, bleeding-Journal of Hepatology 201free survival in patients treated with a combination of
drugs + endoscopic band ligation was 53% at two years, which
is clearly unsatisfactory. This might be improved by adding a
drug that enhances the portal pressure-lowering effect of
beta-blockers and that has the potential to improve liver function
– this drug could be a statin. Another potential scenario is the
prophylaxis of the development of varices or clinical decompen-
sation, since no drug has proved effective so far in these
situations. However, due to the small risk of variceal formation
(around 6% per year) or of clinical decompensation, to prove
the beneﬁt of statins in this setting would require a large trial
with a very long follow-up, which is unlikely to be done in the
absence of commercial interests or strong support from public
agencies.Tetrahydrobiopterin supplementation
Tetrahydrobiopterin (Fig. 4)(BH4) is an essential cofactor for the
adequate generation of NO by NOS enzymes [14–16]. If adequate
quantities of BH4 are not present, a situation known as NOS
uncoupling takes place and the production of NO is decreased.
Studies from our lab [13] have shown that in cirrhotic livers there
is a deﬁciency of BH4, secondary to a reduction in the expression
and activity of Guanosine-5’-triphosphate cyclohydrolase I (GTP-
CHI), the limiting enzyme in BH4 synthesis, which is associated
with decreased NOS activity and NO availability. In cirrhotic rats,
administration of BH4 for three days increased liver NOS activity
and cGMP levels and signiﬁcantly reduced portal pressure. Ame-
lioration of portal hypertension was associated with a normaliza-0 vol. 53 j 558–567 561
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Reviewtion of arterial pressure. These data support the concept that tet-
rahydrobiopterin supplementation may represent a new and
effective therapeutic strategy for portal hypertension. [37,65].Portal pressure
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Fig. 5. Transfection with adenovirus encoding EC-SOD improves the endo-
thelial dependent vasorelaxation in perfused cirrhotic livers (upper panel)
and decreases portal pressure in vivo in cirrhotic rats (lower panel). (Modiﬁed
from Laviña et al. Gut 2009).Antioxidant therapy
In several vascular disorders it has been demonstrated than an
increase in the reactive oxygen species (ROS) superoxide (O2 ),
by rapidly reacting with NO [66], promotes a marked reduction
in NO bioavailability followed by an increase in vascular tone
[67–70]. Our group has recently demonstrated that this also hap-
pens in the cirrhotic liver. This further demonstrates that in
chronic liver disease, reduced intra-hepatic NO bioavailability is
due not only to the consequence of a reduction in its production
by eNOS synthase, but also to an increase in scavenging by
increased levels of superoxide.
We have recently shown that increased O2 levels in the cir-
rhotic liver is associated with reduced superoxide dismuatse
(SOD) activity, the enzyme dismutating O2 to H2O2, suggesting
that this maybe its mechanism. Furthermore, this study clariﬁed
that reduced SOD activity is due to decreased protein expression
of the cytoplasmic and mitochondrial SOD, but not of the extra-
cellular SOD isoform [38]. Interestingly, the study demonstrated
that cyclooxygenase (COX) or xanthine oxidase (XO) inhibition
markedly reduced intra-hepatic O2 levels, which points out that
these enzymatic systems are potential sources of O2 in cirrhosis
[38]. Thus, an increased production of superoxide and a dimin-
ished degradation are the causes of the increased superoxide lev-
els observed in the cirrhotic livers. Increased O2 in cirrhotic livers
was associated with a signiﬁcant increase in nitrotirosinated pro-
teins, a well recognized marker of the reaction of O2 with NO
[38]. The relationship between NO bioavailability and O2 content
in the liver is further supported by our experiments in sinusoidal
endothelial cells (SEC) demonstrating that NO bioavailability is
modulated by O2 . Indeed, increasing O

2 content in SEC by incu-
bating with a SOD inhibitor was associated with a marked fall
in NO bioavailability [38]. Further, abolition of the increase in562 Journal of Hepatology 201O2 using SOD supplementation was followed by a partial restora-
tion in NO bioavailability.
All these data strongly suggest that oxidative stress may con-
tribute to reduced NO bioavailability in cirrhotic livers, and
emphasize that antioxidant therapy, by removing O2 from the
cirrhotic livers, could be a new therapeutic strategy to improve
intra-hepatic NO bioavailability and to ameliorate hepatic vascu-
lar tone in cirrhosis. In that regard, transfection of cirrhotic rats
with portal hypertension with adenovirus encoding extracellular
SOD (EcSOD) resulted in a marked reduction in O2 , in enhanced
NO bioavailability (as estimated by the hepatic levels of cGMP),
and decreased liver nitrotyrosinated proteins [35]. These molec-
ular effects were associated with a signiﬁcant improvement in
the endothelium-dependent vasodilatation to acetylcholine and,
more importantly, promoted a signiﬁcant reduction of portal
pressure in vivo without signiﬁcant changes in MAP [35]. Reduc-
tion in portal pressure averaged 13.3%. This is similar to that
observed in other studies aimed at reducing portal pressure in
cirrhotic rats through other strategies, such as the administration
of non-selective beta-blockers [71] (Fig. 5).0 vol. 53 j 558–567
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This study provided evidence, for the ﬁrst time in vivo, that
decreasing hepatic O2 levels, by increasing SOD activity (i.e. an
antioxidant treatment), may represent an effective strategy to
improve NO bioavailability within the liver. Further support for
this concept comes from studies supplementing ascorbic acid
in patients with cirrhosis [36]. Ascorbic acid (vitamin C), is a
potent antioxidant that has consistently been shown to improve
NO-dependent vasodilatation in vascular beds of patients with
conditions characterized by marked endothelial dysfunction,
such as hypertension, diabetes, hypercholesterolemia, and coro-
nary heart disease. In these conditions, the beneﬁcial effect of
acute ascorbic acid administration has been attributed to its
capacity of neutralizing ROS, mainly superoxide (O2 ). Of note, a
study from our group has shown that cirrhotic patients had sig-
niﬁcantly lower ascorbic acid levels and higher malondialdehyde
levels (MDA: a serum marker of oxidative stress) than healthy
controls. Ascorbic acid signiﬁcantly reduced MDA levels and
effectively improved intra-hepatic endothelial dysfunction,
blunting the post-prandial increase in portal pressure [36],
which encourages performing further studies testing antioxi-
dants as adjunctive therapy in the treatment of portal
hypertension.survivalCell proliferation production
ANGIOGENESIS
Fig. 6. Schematic illustration of the vascular endothelial growth factor (VEGF)
signalling pathway. There is now much evidence that VEGF receptor-2 (VEGFR-
2) is the major mediator of VEGF-driven responses in endothelial cells and it is
considered to be a crucial signal transducer in both physiologic and pathologic
angiogenesis. The binding of VEGF to VEGFR-2, a protein tyrosine kinase that is
directly activated by ligand-receptor interaction, allows the receptor to activate a
range of signal transduction molecules, such as phospholipase C gamma (PLCc)
and phosphatidylinositol 3-kinase (PI3K). Activation of PLCc cleaves phosphati-
dylinositol 4,5-bisphosphate (PIP2) to form diacylglycerol (DAG) and D-myo-
inositol-1,4,5-trisphosphate (IP3). DAG binds to and activates protein kinase C
(PKC), which plays a crucial role in VEGF mitogenic signalling via the Raf-MEK-
ERK (mitogen activated protein kinase kinase/extracellular signal-regulated
kinase) pathway. IP3 regulates intracellular Ca2+ by binding to the IP3 receptor
on the endoplasmic reticulum and stimulating Ca2+ release from the endoplasmic
reticulum. Free intracellular Ca2+ can bind to calmodulin, and this Ca2+-
calmodulin complex activates endothelial nitric oxide synthase (eNOS), which
in turn increases nitric oxide (NO) synthesis. Upon ligand binding to VEGFR-2,
PI3K is also activated leading to activation of the protein kinase Akt, which in turn
phosphorylates eNOS and increases NO production. Akt activation can also
promote endothelial cell survival.Role of angiogenesis in portal hypertension
As already mentioned, the two main hemodynamic factors lead-
ing to the portal hypertensive syndrome are the increased resis-
tance to portal blood ﬂow through the cirrhotic liver, and the
development of a hyperdynamic splanchnic circulatory state. In
this state, an increase in blood ﬂow in splanchnic organs drains
into the portal vein and a subsequently increases portal venous
inﬂow which represents a signiﬁcant factor maintaining and
worsening portal hypertension [1,2].
Another characteristic disturbance of portal hypertension is
the formation of an extensive network of portosystemic collateral
vessels, which include the esophageal and gastric varices [1,2]. In
addition to varices and bleeding, collateral vessels result in
shunting of portal blood into the systemic circulation, causing
high systemic concentrations of several substances normally
metabolized by the liver, such as drugs, toxins, hormones, and
bacteria, which contribute to major complications of chronic liver
disease, including portosystemic encephalopathy and sepsis [1,2].
Traditionally, the increased splanchnic blood ﬂow has been
attributed to an overproduction of endogenous vasodilators and
a decreased vascular reactivity to vasoconstrictors [1,2], while
the formation of collaterals has been considered a mechanical
consequence of the increased portal pressure that will result in
the opening and dilatation of pre-existing vascular channels at
sites of anatomical communications between the portal and sys-
temic circulations [1,2].
However, recent studies from our laboratory challenge these
concepts by demonstrating that angiogenesis, the formation of
new blood vessels [72–75], plays a pivotal role in the develop-
ment and maintenance of splanchnic hyperemia and portosys-
temic collateralization. Importantly, growing evidence suggests
that pathological angiogenesis is also involved in the establish-
ment of the abnormal angioarchitecture distinctive of the cir-
rhotic liver, and is also intimately related to ﬁbrogenesis
[76,77]. Therefore, angiogenesis could also contribute to an
increased intra-hepatic resistance in portal hypertension and
liver cirrhosis.Journal of Hepatology 201Evidence supporting a role for angiogenesis in the pathogene-
sis of portal hypertension includes recent investigations demon-
strating that VEGF, a potent angiogenic factor [36], is
overexpressed in splanchnic organs from portal hypertensive ani-
mals [37,66]. The VEGF signalling cascade is schematically shown
in Fig. 6.
The expression of VEGF receptor-2 (VEGFR-2) and the endo-
thelial cell marker CD31 [67] is also increased in the splanchnic
territory in experimental models of portal hypertension
[37,66]. These and other studies provided evidence of increased
VEGF-driven splanchnic angiogenesis in portal hypertensive ani-
mals and in cirrhotic patients [68–71].
The precise mechanism triggering VEGF-dependent angiogen-
esis in portal hypertension remains speculative, but several fac-
tors known to occur in portal hypertension, such as tissue0 vol. 53 j 558–567 563
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hypoxia, cytokines, and mechanical stress have been shown to
promote VEGF expression in various tissues and cell types
[32,33].
Recent studies have determined the effects of several angio-
genesis inhibitors, with different modes of action, in experimen-
tal models of portal hypertension [74,78]. These studies
demonstrated that treatment with VEGFR-2 blockers from the
induction of portal hypertension markedly decreased the forma-
tion of portosystemic collateral vessels (by 50–65%) and reduced
splanchnic vascularization and portal venous inﬂow in rodent
models of portal hypertension [74,78]. These ﬁndings indicate
that angiogenesis is involved in the development of the portosys-
temic collateral and in the maintenance of an increased portal
venous inﬂow, and strongly support that agents interfering with
the VEGF/VEGFR-2 signalling pathway may potentially be used to
prevent these complications of portal hypertension.
Furthermore, recent studies have shown that therapeutic
strategies directed at inhibiting angiogenesis may have clinical
importance in the treatment of established portal hypertension
in chronic liver disease [75,79] and angiogenesis in liver diseases
[80]. In this regard, it should be noted that in the process of neo-
vascularization, VEGF plays a predominant role in the initial
stages of formation of new blood vessels, activating the prolifer-
ation of endothelial cells and formation of endothelial tubules,
while maturation of the newly formed vessels is mainly modu-
lated by the proangiogenic growth factor platelet-derived growth
factor (PDGF). To revert established new blood vessels, multi-tar-
get agents or a combination of agents blocking both VEGF andCBDL-VEH CBDL-S
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decreased liver ﬁbrosis as a consequence of reduced activation of hepatic stellate cells
Hepatology 2009).
564 Journal of Hepatology 201PDGF is required. For example, the administration of a low dose
of the multi-targeted receptor tyrosine kinase inhibitor sorafenib
has produced multi-fold beneﬁcial effects in experimental mod-
els of portal hypertension and cirrhosis, with a 25% reduction in
portal pressure, attenuation of hyperdynamic splanchnic and sys-
temic circulations, a signiﬁcant decrease in the extent of porto-
systemic collaterals, and a remarkable improvement in liver
damage and intra-hepatic ﬁbrosis, inﬂammation, and angiogene-
sis [75] (Fig. 7). Of note, sorafenib has been approved in several
countries worldwide for treatment of renal [81] and hepatocellu-
lar carcinoma [82]. The latter is a common complication of
advanced cirrhosis, which means that sorafenib is currently being
used in patients with portal hypertension.
The potential efﬁcacy of anti-angiogenic drugs in portal
hypertensive and cirrhotic patients will need, however, a very
careful evaluation since the side effects of these drugs can be seri-
ous [83,84]. For instance, it will be necessary to deﬁne a safe and
optimal dose for portal hypertensive patients, which likely will be
much lower than that required to treat patients with cancer [82].
Of note, in our experimental studies we have used doses of anti-
angiogenic agents over one order of magnitude lower than those
used clinically for cancer, which had no noticeable adverse effects
in mice or rats. Another issue of concern is that the formation of
new blood vessels is not only required for growth and develop-
ment, but it is also an important natural process in the adult body
used for healing and reproduction [83]. Treatments that block
angiogenesis could therefore potentially interfere with these
physiological processes [83]. These may be partly overcome byORA
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chnic neovascularization (top panel), and on superior mesenteric artery (SMA)
duct ligated (CBDL) cirrhotic rats (bottom panel). This treatment also resulted in
and diminished inﬂammation (data not shown). (reproduced from Mejias et al.,
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using anti-angiogenic agents that do not interfere with physio-
logical angiogenesis since they act predominantly on pathological
angiogenesis. It has been suggested that drugs blocking placental
growth factor (PLGF) driven angiogenesis may accomplish this
goal in portal hypertensive models [61,84,85].
Despite these drawbacks, however, angiogenesis remains a
very tempting and innovative target in portal hypertension ther-
apy, and researchers are exploring new agents and approaches to
maximize the beneﬁcial effects of anti-angiogenic therapies in
cirrhosis.
Increased hepatic resistance is the primary cause of 
portal hypertension in chronic liver diseases 
Increased hepatic resistance has two components, the 
first is structural while the second is functional 
The molecular pathways of both components are being
delineated 
Both are (almost) totally reversible in experimental 
models, which opens new perspectives for therapeutic 
applications 
Angiogenesis plays an important role in the pathogenesis
of portal hypertension, modulating hepatic stellate cells
activation and fibrogenesis, splanchnic vasodilation and
formation of portal-systemic collaterals  
Because of the multiple factors involved, a rational
therapy should target several pathophysiological 
mechanisms (multitarget therapy)
Translation of these advances into clinical practice is 
soon anticipated
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